Symposium to focus on diagnosis and treatment of broad range of neurological disorders
KANSAS CITY, Mo., July 15, 2013 /PRNewswire-USNewswire/ -- Saint Luke's Neuroscience Institute (SLNI), one of the region's pre-eminent neurological facilities, in conjunction with the University of Missouri-Kansas City (UMKC) School of Medicine and Saint Luke's Hospital of Kansas City (SLH) has opened registration for the Saint Luke's Neuroscience Institute 2013 Symposium.
The SLNI Symposium is targeted toward neurosurgeons, neurologists, neurointensivists, psychiatrists, primary care physicians, family physicians, nurses, case managers and social workers and will feature leading neurologists, neurosurgeons, and neuropsychiatrists speaking about new approaches for diagnosis and treatment of a wide array of neurological illnesses and disorders.
Program highlights include lectures on deep brain stimulation, stroke, epilepsy, Transcranial Magnetic Stimulation, brain tumor surgery, intracranial aneurysms, chronic headaches, multiple sclerosis, and facial pain.
"The topics and treatments to be discussed at the 2013 Symposium offer some of the latest, most ground-breaking advances and treatment techniques in our field," said Darren Lovick, M.D., Saint Luke's Neuroscience Institute co-surgical director. "We are incredibly excited to be able to offer this learning opportunity to physicians and nurses locally and regionally."
The symposium is scheduled for Sept. 20, 2013, and will be held at the Kansas City Public Library- Plaza Branch, 4801 Main Street, Kansas City, MO 64112, between 7:45 a.m. and 5 p.m.. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Missouri-Kansas City School of Medicine and Saint Luke's Hospital of Kansas City. The UMKC School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Missouri-Kansas City School of Medicine designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Healthcare Professionals interested in registering online for the 2013 SLNI Symposium can do so by visiting https://cmetracker.net/UMKC/Catalog. Interested attendees can also view a complete list of the session learning objectives by visiting http://www.med.umkc.edu/cme/objectives.shtml.
About the Saint Luke's Neuroscience Institute
Saint Luke's Neuroscience Institute, a member of Saint Luke's Health System, is a global leader in utilizing both drug and mechanical interventions to block and reverse the permanent and debilitating effects of ischemic strokes. Its legacy of innovation began in 1993 when doctors performed one of the world's first intra-arterial stroke reversal procedures. Since then, Saint Luke's specialists have continued to pioneer new stroke treatments and reverse stroke's debilitating effects for thousands of patients, and is one of the world's most experienced and prolific leaders in the use of Tissue Plasminogen Activator (t-PA), a clot-busting medication for treatment of ischemic stroke. SLNI, headquartered in Kansas City, Missouri, brings together a team of the country's most accomplished neurologists to provide a comprehensive treatment center for the most complex neurological issues, such as stroke, epilepsy, brain tumors, facial pain, Parkinson's disease, Alzheimer's, headaches, aneurysms, and the latest in minimally invasive spinal surgical techniques. SLNI's advancements in neurology have made it a national leader in neurological treatment and care.
About the University of Missouri-Kansas City School of Medicine
The UMKC School of Medicine was founded in 1971 as an innovative combined degree program. From its baccalaureate/MD curriculum to a docent system that emphasizes small group learning, the school has remained a trendsetter in medical education and research. For more information about the UMKC School of Medicine, visit www.med.umkc.edu. You can also find us on Facebook and follow us on Twitter.
SOURCE Saint Luke's Neuroscience Institute